Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Could this phenomena or problem of using untoward

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
jimmy667 Member Profile
 
Followed By 39
Posts 3,508
Boards Moderated 0
Alias Born 10/20/15
160x600 placeholder
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 3/23/2020 8:01:22 AM
Anavex Life Sciences to Webcast 2020 Annual Meeting of Shareholders GlobeNewswire Inc. - 3/23/2020 8:00:10 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 3/9/2020 4:28:38 PM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS) GlobeNewswire Inc. - 2/24/2020 7:00:10 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/20/2020 4:32:14 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:38:56 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
PURA BUY Recommendation at $0.03 Issued By AmericanBulls InvestorsHub NewsWire - 2/7/2020 10:33:33 AM
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates GlobeNewswire Inc. - 2/6/2020 7:00:10 AM
Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference GlobeNewswire Inc. - 2/4/2020 7:00:10 AM
Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Developmen... GlobeNewswire Inc. - 2/3/2020 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020 GlobeNewswire Inc. - 1/30/2020 7:00:10 AM
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Dis... GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 6:00:00 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
jimmy667   Friday, 03/01/19 10:00:30 PM
Re: nidan7500 post# 183453
Post # of 243613 
Could this phenomena or problem of using untoward resources of the FDA on large Amyloid Trials be a consequence of the very User Fee Act that to a large part funds the FDA?
Does not the ones who pay the Piper (FDA) get to call the tune? In other words is the dominance of the FDA by BP facilitated by the User Fee Act (PDUFA) since that is what funds the FDA that BP can chase the resources of the FDA down rabbit holes so they do not have the time and resources to divote to promising or even paradigm shifting new drugs of smaller innovative Biopharm Companies and therefore retain their dominant positions in the Drug Industry?
How would Dr Peter Singe analysis the PDUFA dilemma?
Does not in fact the PDUFA by Act of Congress cede effective command and control of the FDA to the deep pockets of the BPs?
It seems all baby Bios can do is clinically try Orphan Drugs where PDUFA fees are waived or discounted.
What the heck is Bill Gates doing? We need real philanthropists like Andrew Carnegie of a prior era that actually use their wealth to make a difference. (System of public libraries which was a huge benefit to the people of the USA)
Down with the Pharmaceutical Drug User Fee Act. It needs to be abolished as it grants a strangle hold on the FDA by BP.
He who pays the Piper calls the tune. Those same Pigs are always at the Tits of Government as long as the money is Green. As in overcharging Fed programs like Medicaid for the drugs.
Long AVXL. Let her torches burn bright so she can show the way to other innovative Biotechs navigating the mine fields sown by BPs and their lap dog the FDA.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist